REPROCELL Resources Online

REPROCELL Webinars

Online webinars hosted by REPROCELL.

Review of current regulatory issues on ancillary materials and importance of animal origin free products

WebinarAjinomoto20200908_UK

About the Speaker

Dr. Takuya Matsumoto is a researcher at the Institute for BioScience at AJINOMOTO Co., Inc. Dr. Matsumoto received his Ph.D. in Bichemistry from Okayama University in Japan and joined Ajinomoto in 2009. After stints as a Visiting Scientist at Keio University and at Harvard University, he is currently a Senior Researrcher at Ajinomoto, where he developed StemFit AS202 Neural Stem Cell medium. Dr. Matsumoto's research interests include implementation of PSCs in regenerative medicine and the development of high-quality reagents and superior culture systems for clinical use.

MatsumotoHeadshot


CRISPR-SNIPER Gene Editing for Challenging Cases

CRISPR-Webinar-Trim

About the Speaker

Dr. Tsukasa Sugo is CEO and Founder of GenAhead Bio in Fujisawa, Japan. Dr. Sugo earned his BS and Ph.D. degrees from Tokyo University. Prior to founding GenAhead Bio, Dr. Sugo worked at Takeda Pharmaceutical Company, leading research teams in genome editing, nucleic acid research and G-protein coupled receptors. He held a visiting scientist position at Alnylam Pharmaceuticals in the Boston area.

Dr-Sugo-2


Services and Resources for COVID-19 Research

Webinar_Covid_720dpi

 

About the Speakers

Prof. Anne Dickinson is a Professor with the Translational and Clinical Research Institute within the Faculty of Medical Sciences, Newcastle upon Tyne, UK. Prof. Dickinson founded Alcyomics Ltd based on over 30 years experience with a human in vitro skin explant model for predicting graft-versus-host disease (GvHD), a severe allo-immune complication of haematopoietic stem cell transplantation. This skin model (Skimune®) is used within Alcyomics to predict allergy and sensitization to chemicals and drugs, including biologics and cellular therapies. Skimune® is patented in Europe and the US.

Prof.DickensonHeadShot

Dr. Terri Lehman has served as REPROCELL BioServe’s Chief Technical Officer since 1993. Terri is responsible for development and maintenance of all standard operating procedures (SOPs) for all research work, as well as quality control across all products and services.

Prior to BioServe, Terri was a post-doctoral fellow at the National Cancer Institute and National Institutes of Health. At these institutions she helped develop PCR and sequencing techniques to investigate point mutations in the p53 tumor suppressor gene and the ras protooncogene in a variety of human samples. Lehman received her Ph.D. from The Ohio State University in the Department of Physiological Chemistry.

Terri-Lehman
 


Consistent and Efficient hPSC Culture with a Novel Animal-Origin Free Culture System

About the Speaker

Dr. Hajime Onuki received his MD from Kyoto University in Japan in 2013. He then joined Ajinomoto Co., Inc. in the R&D department. In 2018, he joined the amino acids department in the culture media group at Ajinomoto, where he has an interest in developing solutions for cell therapy using pluripotent stem cells.

crop-STTAFJXR-Presenter-OhnukiH


The Development and Application of Advanced Cell Culture Techniques to Construct Models of Human Tissues 

REPROCELLWebinar200213_720p

About the Speaker

Professor Stefan Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, tissue engineering and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 125 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of REPROCELL Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. Professor Przyborski is developing new and innovative ways to manage the growth and function of cultured cells. He is the inventor of Alvetex technology, the market leading scaffold product for three-dimensional cell culture. These enabling technologies have multiple applications and are particularly relevant to bioengineering models of human tissues to advance basic research, safety assessment and drug discovery.

Professor Stefan Przyborski PHOTO


Using Neural Network Activity Readouts in Human iPSC-derived Neuron/Glia Co-Cultures for in Vitro Neurotoxicity Assessment.

REPROCELLWebinarSeriesDec2019

About the Speaker

As the Head of Neuroscience and Co-founder, Dr. Daniel Haag drives the scientific direction of NeuCyte Inc. and leads the development of novel human neural in vitro platforms for neurotoxicity assessment and drug discovery. After graduating from the Technical University of Darmstadt, he prepared his doctoral thesis at the German Cancer Research Center and the University of Heidelberg studying genetic drivers in brain tumors. During his postdoctoral appointment at Stanford University, he became an expert in neural differentiation and direct reprogramming of iPS cells as well as genome engineering and in vitro modeling of CNS disorders.

Daniel Haag_mediumres_3387


Providing Safety Testing Solutions for the Pharmaceutical and Cosmetic Industry

 

About the Speaker

Dr. Shaheda Ahmed graduated as a molecular biologist and then continued her interest in science by successfully completing a PhD in the Department of Clinical Medical Sciences at Newcastle University in 2006. Following her interest in translational medicine, Dr Ahmed went on to work in Hematological Sciences in the field of bone marrow transplant biology before making a successful transition from academia to industry. She is currently utilizing her expertise at Alcyomics Ltd, a spin-out company from Newcastle University, to help provide a service provision for safety testing of biologics and cosmetics, where she holds the position of Scientific Manager. 

Dr Ahmed has broad research interests based around immunogenicity, allergy and skin explant biology with specific research interests in T lymphocyte stimulation and cytokine release in response to sensitizing chemicals and respiratory allergens, drugs and novel compounds. Dr Ahmed also has active interests in the development, validation and application of novel predictive test methods, including 3D models and bio-printed models, which aim to reduce, refine and replace the use of animals in safety assessment.

Dr Shaheda Ahmed


How Pharma is using Fresh Human Tissues to Better Predict Drug Safety and Efficacy

How Pharma is Using Human Fresh Tissues to Better Predict Drug Safety and Efficacy (full)

 

About the Speaker

David Bunton is co-founder and CEO of Biopta Ltd. After graduating from the University of Glasgow with an Honours degree in Physiology, he undertook a PhD in Pharmacology at Glasgow Caledonian University, which led immediately to his appointment as a Lecturer in Physiology and Pharmacology.

David was also a consultant to the Diabetes Education and Training Unit at Glasgow Caledonian and has numerous publications in respiratory and vascular pharmacology, including a number of reviews on the state of the art in human tissue research. He is a member of the British Pharmacological Society and Safety Pharmacology Society, and is an active contributor to the drive towards greater use of human tissues in drug development having co-organised the 2009 human tissue conference at the House of Lords. Email: davidbunton@reprocell.com.

REPROCELL-04.06.18_0852


CRISPR/Cas9 using SNIPER Technology —Managing Challenging Cases

CRISPR-SNIPER Webinar Presentation

 

About the Speaker

Dr. Tsukasa Sugo is CEO and Founder of GenAhead Bio in Fujisawa, Japan. Dr. Sugo earned his BS and Ph.D. degrees from Tokyo University. Prior to founding GenAhead Bio, Dr. Sugo worked at Takeda Pharmaceutical Company, leading research teams in genome editing, nucleic acid research and G-protein coupled receptors. He held a visiting scientist position at Alnylam Pharmaceuticals in the Boston area.

Dr-Sugo-2